SS
LCTX icon

Steve Schonfeld’s Lineage Cell Therapeutics LCTX Stock Holding History

Steve Schonfeld’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,017
Closed -$75.9K – 2817
2026
Q1 		$75.9K Buy
48,017
+34,699
+261% +$58.5K ﹤0.01% 1922
2025
Q4 		$22.2K Buy
+13,318
New +$23.1K ﹤0.01% 1923
2025
Q3 		– Sell
-16,126
Closed -$14.6K – 2402
2025
Q2 		$14.6K Buy
+16,126
New +$9.57K ﹤0.01% 1947
2023
Q2 		– Sell
-22,300
Closed -$33.5K – 2337
2023
Q1 		$33.5K Buy
+22,300
New +$31.1K ﹤0.01% 1803
2021
Q2 		– Sell
-33,574
Closed -$78K – 2132
2021
Q1 		$78K Buy
33,574
+15,841
+89% +$38K ﹤0.01% 1692
2020
Q4 		$32K Buy
+17,733
New +$24.8K ﹤0.01% 1515

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Steve Schonfeld's LCTX Position: Q2 2026 in Review

Steve Schonfeld sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 48,017 shares — an estimated $75.9K sold.

Steve Schonfeld first reported a position in LCTX in Q4 2020 and held it in 6 quarters. The position peaked at $78K in Q1 2021. 131 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Steve Schonfeld reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 48,017 Lineage Cell Therapeutics shares in Q2 2026, an estimated $75.9K.
  • Steve Schonfeld first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 6 quarters.
  • Steve Schonfeld's Lineage Cell Therapeutics position peaked at $78K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.